Abeona Therapeutics: Analyst Forecast Sparks Investor Optimism

Abeona Therapeutics shares concluded the latest trading session at $5.07, with market attention focused squarely on a significant forecast revision from Cantor Fitzgerald that substantially raises expectations for 2025 performance.

The biopharmaceutical company delivered a stronger-than-anticipated third quarter 2025 performance, reporting a loss per share of just $0.10. This figure surpassed analyst consensus estimates of a $0.27 loss by $0.17 per share. Despite this improved bottom-line performance, the company’s revenue for the trailing twelve months remains modest at $400,000.

Major Analyst Firm Boosts Projections

Cantor Fitzgerald has significantly upgraded its earnings outlook for Abeona’s 2025 fiscal year. Research analyst K. Kluska raised the earnings per share (EPS) forecast from $1.15 to $1.33, positioning the new estimate Read more...